{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+A&page=54",
    "query": {
      "intervention": "Placebo Comparator A",
      "page": 54
    },
    "page_size": 10
  },
  "pagination": {
    "page": 54,
    "page_size": 10,
    "total_count": 27155,
    "total_pages": 2716,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+A&page=55&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+A&page=53&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T01:34:00.313Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06077487",
      "title": "Ketamine-assisted Therapy for Advanced GI Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Pain, Acute",
        "Gastrointestinal Cancers",
        "Demoralization"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Ketamine Injectable Product",
          "type": "DRUG"
        },
        {
          "name": "Meaning and Purpose therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Questionnaires",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Brian Anderson, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2024-05-17",
      "completion_date": "2025-01-31",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-11-21T01:34:00.313Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06077487"
    },
    {
      "nct_id": "NCT02642393",
      "title": "Study of Urate Elevation in Parkinson's Disease, Phase 3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Inosine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael Alan Schwarzschild",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 298,
      "start_date": "2016-06",
      "completion_date": "2019-06",
      "has_results": true,
      "last_update_posted_date": "2020-07-28",
      "last_synced_at": "2026-11-21T01:34:00.313Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02642393"
    },
    {
      "nct_id": "NCT03304821",
      "title": "Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral Artery Disease (PAD)"
      ],
      "interventions": [
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 114,
      "start_date": "2017-12-19",
      "completion_date": "2025-07-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-11-21T01:34:00.313Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03304821"
    },
    {
      "nct_id": "NCT00953706",
      "title": "Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Ivacaftor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2009-09",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2015-09-11",
      "last_synced_at": "2026-11-21T01:34:00.313Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00953706"
    },
    {
      "nct_id": "NCT04199104",
      "title": "A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 511,
      "start_date": "2020-02-05",
      "completion_date": "2025-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-11-21T01:34:00.313Z",
      "location_count": 26,
      "location_summary": "Fresno, California • San Marcos, California • Aurora, Colorado + 22 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04199104"
    },
    {
      "nct_id": "NCT02950233",
      "title": "Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "NMDA active",
          "type": "DRUG"
        },
        {
          "name": "Steroid active",
          "type": "DRUG"
        },
        {
          "name": "NMDA placebo",
          "type": "DRUG"
        },
        {
          "name": "Steroid placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Population Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 27,
      "start_date": "2017-05-04",
      "completion_date": "2019-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-11-21T01:34:00.313Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02950233"
    },
    {
      "nct_id": "NCT00371033",
      "title": "Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)"
      ],
      "interventions": [
        {
          "name": "Pregabalin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 324,
      "start_date": "2006-03",
      "completion_date": "2008-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-11-21T01:34:00.313Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Stanford, California • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00371033"
    },
    {
      "nct_id": "NCT01166438",
      "title": "Anticholinergic vs. Botox Comparison Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urge Urinary Incontinence",
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin A (Botox A®)",
          "type": "DRUG"
        },
        {
          "name": "Solifenacin 5mg",
          "type": "DRUG"
        },
        {
          "name": "Solifenacin 10mg",
          "type": "DRUG"
        },
        {
          "name": "Trospium chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NICHD Pelvic Floor Disorders Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 249,
      "start_date": "2010-03",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-11-21T01:34:00.313Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Dearborn",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01166438"
    },
    {
      "nct_id": "NCT04498455",
      "title": "Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Weight Gain Trajectory",
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Prebiotin",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Baylor University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 11,
      "start_date": "2018-09-30",
      "completion_date": "2019-02-15",
      "has_results": false,
      "last_update_posted_date": "2020-08-17",
      "last_synced_at": "2026-11-21T01:34:00.313Z",
      "location_count": 1,
      "location_summary": "Waco, Texas",
      "locations": [
        {
          "city": "Waco",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04498455"
    },
    {
      "nct_id": "NCT06704178",
      "title": "A Study to Evaluate the Effects of a Dietary Supplement on Children's Health and Development Outcomes.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Height",
        "Cognitive Function",
        "Weight Gain"
      ],
      "interventions": [
        {
          "name": "NuBest Tall Growth Protein Powder",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Powder",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "NuBest",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "10 Years to 16 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-06-12",
      "completion_date": "2025-02-16",
      "has_results": true,
      "last_update_posted_date": "2025-07-24",
      "last_synced_at": "2026-11-21T01:34:00.313Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06704178"
    }
  ]
}